The quality of a target ranking is bounded by the quality of the underlying data. This is not a platitude; it is a concrete operational constraint with specific failure modes. Omics data that has not been appropriately preprocessed will produce misleading target rankings even when the scoring methodology is sound. Getting the data layer right is prerequisite work, not an optional refinement.
RNA-seq Quality: What to Check Before Analysis
Bulk RNA-seq data quality assessment starts with the sequencing metrics: total read count, mapping rate to the reference genome, duplication rate, and the distribution of read coverage across transcript bodies. A sample with a mapping rate below 70% warrants investigation -- likely either poor sample quality or a contamination issue. High duplication rates (above 50-60%) may indicate low-complexity libraries that will reduce sensitivity for lowly expressed genes. Uneven coverage with strong 3' bias often indicates RNA degradation, which will cause systematic underestimation of expression for genes with longer transcripts.
Beyond sequencing metrics, checking the distribution of library sizes across samples is important before normalization. Large differences in sequencing depth between samples (greater than 5-10 fold) can introduce artifacts even after normalization. Checking for outlier samples using PCA or hierarchical clustering before any downstream analysis is standard practice: a sample that clusters separately from all others in its condition group should be investigated before being included in the analysis.
Proteomics Data: Specific Challenges
Mass spectrometry-based proteomics data has different quality indicators. Peptide identification rate, protein coverage, and the distribution of precursor ion intensity across samples are the first-pass checks. Samples with very low protein identification counts may have failed at the sample preparation step and should be excluded or reprocessed. Missing value patterns are particularly important in proteomics: unlike RNA-seq where a gene with no reads can be confidently assigned zero expression, a missing protein identification in proteomics can reflect true absence or simply a detection sensitivity limitation.
For quantitative proteomics, the choice of normalization strategy matters more than is often appreciated. Global median normalization assumes that the overall protein content is similar across samples, which is generally reasonable for cell culture but may not hold for patient tissue samples with different cell type compositions. When comparing tumor and normal tissue, for example, differences in cell type composition contribute to apparent expression differences that are not directly informative about which specific proteins are dysregulated in the tumor cells themselves.
GWAS Summary Statistics: What to Verify
When integrating GWAS summary statistics from public resources, verifying that the summary statistics are what they appear to be is important. Key checks include: confirming the genomic build (GRCh37 vs GRCh38 -- a mismatch will mislocate variants), verifying that effect allele and other allele assignments are consistent with the reference panel being used for downstream analysis, and checking that the sample sizes and case-control proportions match the study's published methods. Summary statistics that have been downloaded from intermediate sources sometimes have column naming inconsistencies or missing fields that create downstream analysis errors.
For fine-mapping analyses that aim to identify the likely causal variant in a GWAS locus, the reference population for LD computation should match the ancestry of the GWAS cohort as closely as possible. Using European-ancestry LD reference panels for GWAS data collected primarily from East Asian populations will produce misleading fine-mapping results.
Batch Effects: The Most Common Source of Confounding
Batch effects in omics data are the most frequent source of downstream analytical errors in multi-study integration. Batch effects arise when technical variation introduced at different stages of sample preparation, data collection, or processing creates systematic differences between groups of samples that are not related to the biological variables of interest. They are ubiquitous in practice because samples are rarely all processed simultaneously under identical conditions.
The challenge is that batch effects are not always detectable from a single PCA or clustering analysis, particularly when batch assignment correlates with biological variables. If all samples from one clinical site were processed in one batch and all samples from another site in a second batch, and if the clinical sites have different patient demographics or disease severity distributions, then apparent batch effects and real biological differences are confounded and cannot be cleanly separated.
The practical implication is that study design matters enormously for multi-omics integration. Datasets where biological groups of interest are distributed across batches -- or better, where samples were randomized to processing batches -- are much more useful for integration than datasets where batch and biological group are confounded. When integrating publicly available data, examining the study metadata for batch assignment information is a prerequisite step, not an afterthought.
Cell Type Composition Deconvolution
For bulk RNA-seq and proteomics data from tissue samples, cell type composition is a major source of confounding. A tissue that contains 40% immune cells in one condition and 15% in another will show differential expression of hundreds of immune cell marker genes not because those genes are dysregulated at the cellular level but because the proportions of immune cells in the tissue are different. Bulk omics data does not directly measure cell-type-specific gene expression; it measures population averages across all cells present in the sample.
Computational deconvolution methods can estimate cell type proportions from bulk expression data and partially correct for composition differences, but these methods rely on reference gene expression signatures for the relevant cell types and have limited accuracy when cell type compositions are very different from the training data. Single-cell RNA-seq provides direct cell-type-resolved expression data and avoids this problem, at the cost of substantially higher per-sample expense and more complex analytical workflows.
Quality Gates Before Integration
The practical recommendation is to establish explicit quality gates before any data enters a multi-omics integration pipeline. For RNA-seq, this means minimum mapping rate, minimum library size, and maximum duplication rate thresholds that must be met before a sample is included. For proteomics, minimum protein identification count and maximum missing-value fraction thresholds serve the same purpose. These gates are not arbitrary; they should be set based on empirical assessment of which samples fall outside the range where normalization can recover reliable estimates.
Documenting which samples failed quality gates, and why, is as important as documenting which samples passed. A downstream analysis that looks puzzling -- a target that scores unexpectedly or a cluster that does not make biological sense -- is often explained by tracing back to which samples were included or excluded and why. Without that documentation, troubleshooting requires reconstructing decisions that should have been recorded at the time they were made. Building quality gate documentation into the standard workflow rather than treating it as an optional extra step is one of the simplest ways to improve the long-run reliability of omics data analysis.